European Commission approves upadacitinib (Rinvoq)-first JAK Inhibitor for use in adults & adolescents with Moderate to Severe Atopic Dermatitis. UPA is approved for atopic dermatitis in other nations, Russia, Saudi Arabia; pending review in US https://t.co/hiPkJoJCex